TearLab Corporation (TEAR): Price and Financial Metrics

TearLab Corporation (TEAR): $0.06

0.00 (-1.86%)

POWR Rating

Component Grades








Add TEAR to Watchlist
Sign Up

Industry: Miscellaneous




#NR of NR

in industry

TEAR Price/Volume Stats

Current price $0.06 52-week high $0.22
Prev. close $0.06 52-week low $0.02
Day low $0.06 Volume 20,200
Day high $0.06 Avg. volume 97,724
50-day MA $0.06 Dividend yield N/A
200-day MA $0.05 Market Cap 727.28K

TEAR Stock Price Chart Interactive Chart >

TEAR Latest News Stream

Event/Time News Detail
Loading, please wait...

TEAR Latest Social Stream

Loading social stream, please wait...

View Full TEAR Social Stream

Latest TEAR News From Around the Web

Below are the latest news stories about TearLab Corp that investors may wish to consider to help them evaluate TEAR as an investment opportunity.

TearLab reports Q1 results

TearLab (TEAR): Q1 GAAP EPS of -$0.12.Revenue of $5.09M (-10.4% Y/Y)Press Release...

Seeking Alpha | June 26, 2020

TearLab Announces Acquisition By Accelmed Partners And Related $25 Million Investment

TearLab Corporation (OTCQB: TEAR), a leader in Ocular Surface Diagnostics, today announced it has entered into a definitive agreement pursuant to which Accelmed Partners II (AP-II) will acquire TearLab. In connection with the acquisition, AP-II has agreed to an investment of $25 million over two tranches that will occur in conjunction with the company delisting from the "over the counter" OTCQB market and TearLab and its senior secured lender, CR Group, has agreed to restructure the terms of the company's outstanding senior secured indebtedness. Post transaction, TearLab will be a private company and AP-II will be the controlling shareholder. Proceeds from the AP-II investment will be used to pay down a portion of TearLab's existing debt, and fund both organic and inor...

Yahoo | May 11, 2020

TearLab Corporation Confirms Merger Discussions

Any transaction would be subject to the approval of TearLab’s board of directors and stockholders, as well as other customary conditions contained in a definitive agreement. TearLab cautioned that no agreement has been reached. TearLab also noted that there cannot be any assurance that an agreement will be reached or, if an agreement is reached, that a transaction will be completed.

Yahoo | May 7, 2020

TearLab Resubmits 510(k) for U.S. FDA Clearance of the TearLab Discovery™ MMP-9 Test

The submission covers the TearLab Discovery™ Platform and its single-use, disposable Test Card measuring the inflammatory biomarker, matrix metalloproteinase 9 (MMP-9). TearLab Discovery™ will also be capable of performing the Company’s current FDA cleared tear osmolarity test.

Yahoo | April 22, 2020

Klinik Health Ventures Corp. Announces Qualifying Transaction

The LOI outlines the principal terms and conditions which will result in a reverse takeover of Klinik by NeuPath (the "Transaction"). Klinik is a Capital Pool Company and intends for the Transaction to constitute its Qualifying Transaction, as such terms are defined in the policies of the TSX Venture Exchange (the "TSXV").

Yahoo | March 20, 2020

Read More 'TEAR' Stories Here

TEAR Price Returns

1-mo N/A
3-mo N/A
6-mo N/A
1-year N/A
3-year N/A
5-year -31.82%
2023 N/A
2022 N/A
2021 N/A
2020 0.00%
2019 -55.68%

Continue Researching TEAR

Here are a few links from around the web to help you further your research on TearLab Corp's stock as an investment opportunity:

TearLab Corp (TEAR) Stock Price | Nasdaq
TearLab Corp (TEAR) Stock Quote, History and News - Yahoo Finance
TearLab Corp (TEAR) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!